Ocugen to Participate in a Fireside Chat at Chardan’s 8th Annual Genetic Medicines Conference
Ocugen, Inc. (NASDAQ: OCGN), a biotechnology company specializing in gene and cell therapies and vaccines, has announced its participation in Chardan's 8th Annual Genetic Medicines Conference. The event will take place on September 30-October 1, 2024 in New York.
Dr. Arun Upadhyay, Chief Scientific Officer and Head of Research & Development at Ocugen, will engage in an in-person fireside chat on September 30 at 10:30 a.m. ET. The session, moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, will focus on Ocugen's modifier gene therapy approach for retinal diseases and the progress of ongoing clinical trials for retinitis pigmentosa, geographic atrophy, and Stargardt disease.
The fireside chat will be accessible via a live video webcast on the Ocugen investor site. Additionally, Ocugen's executive team will conduct one-on-one meetings with investors to discuss the company's business and clinical development strategy.
Ocugen, Inc. (NASDAQ: OCGN), un'azienda biotecnologica specializzata in terapie geniche e cellulari e vaccini, ha annunciato la sua partecipazione alla 8ª Conferenza Annuale sui Medicinali Genetici di Chardan. L'evento si svolgerà dal 30 settembre al 1 ottobre 2024 a New York.
Il Dott. Arun Upadhyay, Chief Scientific Officer e Responsabile della Ricerca e Sviluppo di Ocugen, parteciperà a un incontro informale dal vivo il 30 settembre alle 10:30 a.m. ET. La sessione, moderata da Daniil Gataulin, PhD, Senior Biotech Research Analyst, si concentrerà sull'approccio di terapia genica modificatrice per le malattie retiniche di Ocugen e sui progressi dei trial clinici in corso per la retinite pigmentosa, l'atrofia geografica e la malattia di Stargardt.
La chiacchierata informale sarà accessibile tramite un webcast video in diretta sul sito per gli investitori di Ocugen. Inoltre, il team esecutivo di Ocugen condurrà incontri individuali con gli investitori per discutere la strategia aziendale e di sviluppo clinico dell'azienda.
Ocugen, Inc. (NASDAQ: OCGN), una compañía biotecnológica especializada en terapias génicas y celulares y vacunas, ha anunciado su participación en la 8ª Conferencia Anual de Medicamentos Genéticos de Chardan. El evento se llevará a cabo del 30 de septiembre al 1 de octubre de 2024 en Nueva York.
El Dr. Arun Upadhyay, Director Científico y Jefe de Investigación y Desarrollo de Ocugen, participará en un diálogo informal en persona el 30 de septiembre a las 10:30 a.m. ET. La sesión, moderada por Daniil Gataulin, PhD, Analista de Investigación Biotecnológica Senior, se centrará en el enfoque de terapia génica modificadora para enfermedades retinianas de Ocugen y en los avances de los ensayos clínicos en curso para la retinitis pigmentosa, la atrofia geográfica y la enfermedad de Stargardt.
El diálogo informal estará disponible a través de un webcast de video en vivo en el sitio de inversores de Ocugen. Además, el equipo ejecutivo de Ocugen realizará reuniones individuales con los inversores para discutir la estrategia empresarial y de desarrollo clínico de la compañía.
Ocugen, Inc. (NASDAQ: OCGN), 유전자 및 세포 치료와 백신을 전문으로 하는 생명공학 회사가 차르단 제8회 연례 유전자 의약품 회의에 참여하겠다고 발표했습니다. 이 행사는 2024년 9월 30일부터 10월 1일까지 뉴욕에서 열립니다.
Ocugen의 최고 과학 책임자이자 연구개발 책임자인 Arun Upadhyay 박사는 9월 30일 오전 10시 30분 ET에 대면 화상 대화에 참여합니다. Daniil Gataulin 박사가 진행하는 이 세션은 Ocugen의 망막 질환에 대한 변형 유전자 치료 접근법과 망막 색소변성증, 지리적 위축 및 스타가르트병에 대한 진행 중인 임상 시험의 진전을 다룹니다.
화상 대화는 Ocugen 투자자 사이트를 통해 실시간 비디오 웹캐스트로 접근할 수 있습니다. 또한, Ocugen의 경영진은 회사의 비즈니스 및 임상 개발 전략에 대해 논의하기 위해 투자자와 일대일 회의를 진행할 예정입니다.
Ocugen, Inc. (NASDAQ: OCGN), une entreprise de biotechnologie spécialisée dans les thérapies géniques et cellulaires ainsi que les vaccins, a annoncé sa participation à la 8ème Conférence Annuelle sur les Médicaments Génétiques de Chardan. Cet événement se déroulera du 30 septembre au 1er octobre 2024 à New York.
Le Dr Arun Upadhyay, Directeur Scientifique et Responsable de la Recherche et Développement chez Ocugen, participera à une conversation informelle en personne le 30 septembre à 10h30 ET. La session, modérée par Daniil Gataulin, PhD, Analyste Senior en Recherche Biotech, se concentrera sur l'approche de thérapie génique modifiée pour les maladies rétiniennes d'Ocugen et les progrès des essais cliniques en cours pour la rétinite pigmentaire, l'atrophie géographique et la maladie de Stargardt.
Cette conversation informelle sera accessible via un webinaire vidéo en direct sur le site des investisseurs d'Ocugen. De plus, l'équipe dirigeante d'Ocugen tiendra des réunions individuelles avec les investisseurs pour discuter de la stratégie commerciale et de développement clinique de l'entreprise.
Ocugen, Inc. (NASDAQ: OCGN), ein Biotechnologieunternehmen, das sich auf Gen- und Zelltherapien sowie Impfstoffe spezialisiert hat, hat seine Teilnahme an der 8. jährlichen Konferenz für genetische Arzneimittel von Chardan angekündigt. Die Veranstaltung findet vom 30. September bis 1. Oktober 2024 in New York statt.
Dr. Arun Upadhyay, Chief Scientific Officer und Leiter der Forschung und Entwicklung bei Ocugen, wird am 30. September um 10:30 Uhr ET an einem persönlichen informellen Gespräch teilnehmen. Die Sitzung, moderiert von Daniil Gataulin, PhD, Senior Biotech Research Analyst, wird sich auf Ocugens modifizierte Gentherapieansatz für Netzhauterkrankungen und die Fortschritte bei laufenden klinischen Studien zu Retinitis pigmentosa, geografischer Atrophie und Stargardt-Krankheit konzentrieren.
Das informelle Gespräch wird über einen live Video-Webcast auf der Investoren-Website von Ocugen zugänglich sein. Darüber hinaus wird das Management-Team von Ocugen eins-zu-eins-Meetings mit Investoren abhalten, um die Geschäfts- und klinische Entwicklungsstrategie des Unternehmens zu besprechen.
- None.
- None.
MALVERN, Pa., Sept. 24, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Arun Upadhyay, Chief Scientific Officer, Head of Research & Development, will participate in an in-person fireside chat moderated by Daniil Gataulin, PhD, Senior Biotech Research Analyst, at Chardan’s 8th Annual Genetic Medicines Conference being held September 30-October 1, 2024 in New York, New York.
“I am excited to speak about Ocugen’s groundbreaking modifier gene therapy approach in treating retinal diseases and on the progress of our ongoing clinical trials for retinitis pigmentosa, geographic atrophy, and Stargardt disease,” said Dr. Upadhyay. “Chardan’s Genetic Medicines Conference provides the opportunity to engage with the investor community and share Ocugen’s mission among these important stakeholders.”
In addition to Dr. Upadhyay’s session, members of Ocugen’s executive team will conduct one-on-one meetings to showcase the Company’s business and clinical development strategy.
Details regarding the fireside chat are as follows:
Date: September 30, 2024
Time: 10:30 a.m. ET
Location: Westin Grand Central, New York, NY
Webcast Link: https://wsw.com/webcast/chard19/ocgn/1909908
A live video webcast of the fireside chat will be available on the events page of the Ocugen investor site.
About Ocugen, Inc.
Ocugen, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines that improve health and offer hope for patients across the globe. We are making an impact on patients’ lives through courageous innovation—forging new scientific paths that harness our unique intellectual and human capital. Our breakthrough modifier gene therapy platform has the potential to treat multiple retinal diseases with a single product, and we are advancing research in infectious diseases to support public health and orthopedic diseases to address unmet medical needs. Discover more at www.ocugen.com and follow us on X and LinkedIn.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, which are subject to risks and uncertainties. We may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from our current expectations. These and other risks and uncertainties are more fully described in our periodic filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that we file with the SEC. Any forward-looking statements that we make in this press release speak only as of the date of this press release. Except as required by law, we assume no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact:
Tiffany Hamilton
Head of Communications
Tiffany.Hamilton@ocugen.com
FAQ
When and where is Ocugen (OCGN) participating in Chardan's Genetic Medicines Conference?
Who will represent Ocugen (OCGN) at the Chardan conference fireside chat?
What topics will Ocugen (OCGN) discuss during the Chardan conference fireside chat?
How can investors access Ocugen's (OCGN) fireside chat at the Chardan conference?
